Table 3.
Positive aPL antibodies in C-APS patients versus controls.
| Controls (n = 306) | APS (n = 156) | OR | P | |
|---|---|---|---|---|
| aB2GPI IgG | 2 (0.6%) | 14 (8.9%) | 14.9 | <0.0001 |
| aB2GPI IgM | 3 (0.9%) | 8 (5.1%) | 5.4 | 0.0146 |
| aB2GPI IgA | 5 (1.6%) | 45 (28.8%) | 24.4 | <0.0001 |
| aCL IgG | 3 (0.9%) | 17 (10.8%) | 12.3 | <0.0001 |
| aCL IgM | 2 (0.6%) | 8 (5.1%) | 8.2 | 0.0053 |
| aCL IgA | 3 (0.9%) | 8 (5.1%) | 5.5 | 0.0148 |
| aB2GP1 IgA (isolated) | 5 (1.6%) | 35 (22.4%) | 17.4 | <0.0001 |
| aCL or aB2GPI (IgG or IgM) | 6 (2.0%) | 22 (14.1%) | 8.2 | <0.0001 |
| aCL or aB2GPI any isotype | 13 (4.2%) | 61 (39.1%) | 14.5 | <0.0001 |